Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Stanford Medicine

Sites in Stanford & Palo Alto, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1368
Shown on this page
12
Current sort
Recently updated
Campus scope
Stanford Medicine, Stanford & Palo Alto, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Stanford Medicine, Stanford & Palo Alto, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1081–1092 of 1,368 matching trials with a site at Stanford Medicine, Stanford & Palo Alto, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1 Interventional

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

NCT06138132
Status at this site: Recruiting
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions
KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen
Biological · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 6, 2026, 7:07 AM EST
Recruiting No phase listed Observational

Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds)

NCT06847282
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Muscular Dystrophy, Facioscapulohumeral
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
5 Years to 17 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Palo Alto, California • Iowa City, Iowa • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Nov 6, 2026, 7:07 AM EST
Not yet recruiting Phase 1Phase 2 Interventional

Sonication-based OCD Neurosurgical Intervention Via Capsulotomy

NCT06131502
Site status not listed — check the official record
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
25 Years to 64 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Palo Alto, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Nov 6, 2026, 7:07 AM EST
Active, not recruiting Not applicable Interventional

Roadmap to Parenthood: Testing the Efficacy of a Decision Aid and Planning Tool for Family Building After Cancer

NCT06050135
Site status not listed — check the official record
View directory record Official record
Conditions
Quality of Life, Parenthood Status
Interventions
Roadmap to Parenthood, Informational Booklet
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Nov 6, 2026, 7:07 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Parent-Mediated Intervention Targeting Insistence on Sameness for Autistic Children

NCT06472115
Status at this site: Recruiting
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism
Interventions
Supportive Parenting for Anxious Childhood Emotions (SPACE) for insistence on sameness (IS)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
6 Years to 11 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Nov 6, 2026, 7:07 AM EST
Recruiting Phase 3 Interventional

Biomarker-guided rTMS for Treatment Resistant Depression

NCT04041479
Status at this site: Recruiting
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder
Interventions
Repetitive Transcranial Magnetic Stimulation
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
22 Years to 65 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Nov 6, 2026, 7:07 AM EST
Active, not recruiting Phase 3 Interventional Results available

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

NCT02811861
Site status not listed — check the official record
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Lenvatinib, Everolimus, Pembrolizumab, Sunitinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,069 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
35
States / cities
Stanford, California • Boca Raton, Florida • Fort Myers, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Nov 6, 2026, 7:07 AM EST
Active, not recruiting No phase listed Observational

Diagnostic and Prognostic Biomarkers for High-impact Chronic Pain: Development and Validation

NCT04994249
Site status not listed — check the official record
View directory record Official record
Conditions
Chronic Musculoskeletal Pain, Pain, Pain, Chronic, Joint Pain
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Nov 6, 2026, 7:07 AM EST
Recruiting No phase listed Observational

The APS Phenotyping Study

NCT06521502
Status at this site: Recruiting
View directory record Official record
Conditions
ARDS, Sepsis, Pneumonia
Interventions
Blood collection, Urine Collection, Nasal, oral, and rectal swabs, Stool collection, Heat Moisture Exchange Filter collection, Tracheal Aspirate sample collection, Non-bronchoscopic bronchoalveolar lavage (NBBAL), Surveys, Short physical performance battery, Hand grip strength, CNS Vital Signs, Muscle Ultrasound, Muscle Strength, Spirometry, Lung Diffusion Testing (DLCO), Chest CT Scan
Other · Procedure · Radiation
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
20
States / cities
Fresno, California • Palo Alto, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Nov 6, 2026, 7:07 AM EST
Active, not recruiting Not applicable Interventional

Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) Trial

NCT04095663
Site status not listed — check the official record
View directory record Official record
Conditions
Diverticulitis
Interventions
Partial Colectomy, Medical Management
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
29
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Nov 6, 2026, 7:07 AM EST
Active, not recruiting Phase 3 Interventional Results available

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

NCT02339740
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Interventions
Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tretinoin
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 21 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
152
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Nov 6, 2026, 7:07 AM EST
Active, not recruiting Phase 2 Interventional Results available

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

NCT03794349
Site status not listed — check the official record
View directory record Official record
Conditions
High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma
Interventions
Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
124
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 100 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Nov 6, 2026, 7:07 AM EST

About this Stanford Medicine institution page

What this page lists
ClinicalTrials.gov records that list Stanford Medicine in Stanford & Palo Alto, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Stanford University at any site, browse by condition, or browse by U.S. city.